Systemic inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice.
Systemic inflammatory events, such as infection, increase the risk of stroke and are associated with worse outcome, but the mediators of this clinically important effect are unknown. Our aim here was to elucidate mechanisms contributing to the detrimental effects of systemic inflammation on mild ischemic brain injury in mice. Systemic inflammation was induced in mice by peripheral interleukin-1beta (IL-1beta) challenge and focal cerebral ischemia by transient middle cerebral artery occlusion (MCAo). Systemic inflammation caused an alteration in the kinetics of blood-brain barrier (BBB) disruption through conversion of a transient to a sustained disruption of the tight junction protein, claudin-5, and also markedly exacerbated disruption to the cerebrovascular basal lamina protein, collagen-IV. These alterations were associated with a systemic inflammation-induced increase in neurovascular gelatinolytic activity that was mediated by a fivefold increase in neutrophil-derived matrix metalloproteinase-9 (MMP-9) in the brains of IL-1beta-challenged mice after MCAo. Specific inhibition of MMP-9 abrogated the effects of systemic inflammation on the sustained but not the acute disruption of claudin-5, which was associated with phosphorylation of cerebrovascular myosin light chain. MMP-9 inhibition also attenuated the deleterious impact of systemic inflammation on brain damage, edema, neurological deficit, and incidence of hemorrhagic transformation. These data indicate that a transformation from transient to sustained BBB disruption caused by enhanced neutrophil-derived neurovascular MMP-9 activity is a critical mechanism underlying the exacerbation of ischemic brain injury by systemic inflammation. These mechanisms may contribute to the poor clinical outcome in stroke patients presenting with antecedent infection.
McColl
Barry W
BW
Faculty of Life Sciences, University of Manchester, Manchester M13 9PT, United Kingdom.
Rothwell
Nancy J
NJ
Allan
Stuart M
SM
D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D002545:Brain Ischemia / Q000378:metabolism / Q000503:physiopathology*; D002560:Cerebrovascular Circulation / Q000187:drug effects / Q000502:physiology; D004195:Disease Models, Animal; D005109:Extracellular Matrix / Q000187:drug effects / Q000378:metabolism; D020244:Infarction, Middle Cerebral Artery / Q000378:metabolism / Q000503:physiopathology; D007249:Inflammation / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology*; D018836:Inflammation Mediators / Q000494:pharmacology; D053583:Interleukin-1beta / Q000494:pharmacology; D007700:Kinetics; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D020521:Stroke / Q000378:metabolism / Q000503:physiopathology*; D019108:Tight Junctions / Q000187:drug effects / Q000378:metabolism*
D018836:Inflammation Mediators; D053583:Interleukin-1beta; D020780:Matrix Metalloproteinase 9
Ann N Y Acad Sci. 2006 Nov;1088:251-64
17192571
FASEB J. 2008 Jan;22(1):146-58
17761522
J Neuroimmunol. 2005 Aug;165(1-2):75-82
15964638
Nat Rev Immunol. 2007 Feb;7(2):161-7
17220915
N Engl J Med. 2007 Apr 12;356(15):1517-26
17429083
Eur Neurol. 2005;53(4):188-93
15956787
Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1519-23
15845906
Brain Res. 1996 Nov 11;739(1-2):88-96
8955928
J Cell Biol. 2003 May 12;161(3):653-60
12743111
Neurobiol Dis. 2007 Mar;25(3):496-505
17166728
Brain Res. 2007 Sep 12;1169:98-111
17686468
Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):656-60
12615675
Int J Cancer. 2006 Jun 1;118(11):2721-6
16381009
J Neurochem. 2007 Jul;102(2):501-7
17419808
J Neurosci. 2005 Jul 6;25(27):6401-8
16000631
Nat Rev Immunol. 2006 Jul;6(7):508-19
16778830
Lancet Neurol. 2008 Apr;7(4):341-53
18339349
Stroke. 1986 May-Jun;17(3):472-6
3715945
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8514-9
12824464
Stroke. 2007 Feb;38(2 Suppl):748-52
17261731
Nat Clin Pract Rheumatol. 2005 Dec;1(2):102-10
16932639
J Exp Med. 2003 Sep 1;198(5):725-36
12939340
Crit Rev Biochem Mol Biol. 2002 Dec;37(6):375-536
12540195
Alcohol Clin Exp Res. 2005 Jun;29(6):999-1009
15976526
N Engl J Med. 2004 Dec 16;351(25):2611-8
15602021
J Neurosci. 2007 Apr 18;27(16):4403-12
17442825
Neurobiol Dis. 2006 Jul;23(1):87-96
16624562
Magn Reson Med. 2008 Jun;59(6):1239-49
18421691
J Immunol. 2007 Aug 15;179(4):2576-83
17675520
Biochem Soc Trans. 2007 Nov;35(Pt 5):1163-5
17956302
J Leukoc Biol. 2008 Jul;84(1):207-14
18390930
Trends Immunol. 2001 Oct;22(10):571-9
11574282
J Neurosci. 2000 Sep 15;20(18):7037-42
10995849
Eur Heart J. 2008 Jan;29(1):96-103
18063596
Exp Neurol. 2008 May;211(1):283-91
18355811
Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):1966-75
16778120
Stroke. 2007 May;38(5):1570-7
17395866
Stroke. 1998 Oct;29(10):2189-95
9756602
Stroke. 2002 Mar;33(3):831-6
11872911
Blood. 1997 May 15;89(10):3503-21
9160655
Stroke. 2007 Mar;38(3):1097-103
17255542
J Clin Invest. 2005 May;115(5):1111-9
15864338
J Cereb Blood Flow Metab. 2007 Apr;27(4):697-709
16850029
Proc Natl Acad Sci U S A. 1990 Jan;87(1):16-20
2296576
J Neuroimmunol. 2003 Jun;139(1-2):93-101
12799026
Cerebrovasc Dis. 2006;22(2-3):75-82
16790993
J Neurosci Methods. 1997 Sep 5;76(1):15-20
9334934
J Neurosci. 2001 Oct 1;21(19):7724-32
11567062
Immunol Rev. 1992 Jun;127:119-46
1506003